62413-48-3

Upstream product

• 108-24-7 acetic anhydride 
• 61865-51-8 (1α,2α,3α,4α)-4-acetamido-2,3-epoxycyclopentylmethyl acetate 

Downstream Products

• 75797-17-0 (+/-)-2-amino-6-chloro-9-<2α,3β-dihydroxy-4α-(hydroxymethyl)cyclopent-1α-yl>purine 
• 50619-39-1 (+/-)-2,5-diamino-4-N-<2α,3β-dihydroxy-4α-(hydroxymethyl)cyclopent-1α-yl>amino-6-chloropyrimidine 
• 75829-33-3 (+/-)-(1α,2β,3β,5β)-3-amino-5-(hydroxymethyl)-1,2-cyclopentanediol 

Relevant academic research and scientific papers

Carbocyclic analogues of xylofuranosylpurine nucleosides. Synthesis and antitumor activity

(±)-4α-Amino-2α,3β-dihydroxy-1α-cyclopentanemethanol (6), the carbocyclic analogue of xylofuranosylamine, was synthesized from the previously reported 4α-acetamido-2α,3α-epoxycyclopentane-1α-methanol. Amine 6 was converted to (±)-4α-[(5-amino-6-chloro-4-pyrimidinyl)amino]-2α,3β-dihydroxy-1α-cyc lopentanemethanol (7) by condensation with 5-amino-4,6-dichloropyrimidine. From 7, the carbocyclic analogues of xylofuranosyladenine and xylofuranosyl-8-azaadenine were prepared. In contrast to 9-β-D-xylofuranosyladenine and its 8-aza analogue, the corresponding carbocyclic nucleosides were resistant to deamination by adenosine deaminase. The carbocyclic 8-aza derivative exhibited significant in vivo antitumor activity which varied according to treatment schedule.